



Expanding blood-based risk assessment offerings with LifeLabs® Apolipoprotein (ApoE) Isoform

Our LifeLabs® blood-based Alzheimer's disease (AD) risk assessment portfolio includes testing for ApoE isoforms.

LifeLabs® is committed to expanding the Alzheimer's portfolio of AD and dementia test offerings to support you and your patients through blood-based, easily accessible risk assessment options that can directly impact your care pathway.



Apolipoprotein E (ApoE), the primary brain apolipoprotein, is a biomarker for AD that can be found in the blood or cerebrospinal fluid (CSF).



About half of AD patients carry the E4 allele, compared with 15% in the general population.¹



Genetic counselling support is included with ApoE testing. A genetic counsellor may be very helpful in fully understanding the implications of a patient's genetic results, their potential impact on their health, and any necessary next steps. A genetic counsellor can be reached at 1-844-363-4357 or Ask.Genetics@LifeLabs.com



The presence of an E4 allele is associated with both increased disease risk and decreased average age of onset compared with E2 or E3 alleles.²



This test can be ordered alongside other tests in the LifeLabs Alzheimer's portfolio, such as LifeLabs p-tau217 and Amyloid Beta 42/40, for a more robust risk assessment.



Knowledge of ApoE isoform status is required for patients considering amyloid-modifying therapies due to the risk of amyloid-related imaging abnormalities (ARIA).

Test name	Turnaround time	Volume
LifeLabs® Apolipoprotein E (ApoE) Isoform, Plasma	12 days	1 mL (0.5 mL minimum)

Visit [LifeLabs.com/alzheimers-disease](https://www.lifelabs.com/alzheimers-disease) to learn more about our portfolio or [click here](#) to download requisition.

Stay Informed with LifeLabs

Click the 'Sign up' button below and join our email list to receive the latest news and updates on diagnostic testing for AD and other therapeutic areas.

Sign up

Patient sex, environment, race, ethnicity, and presence of other risk alleles also contribute to the risk of AD associated with ApoE genotype.³

References

1. Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/e4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. *Neuroepidemiology*. 2012;38(1):1-17. doi:10.1159/000334607
2. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. *Neuron*. 2009; 63(3):287-303. doi:10.1016/j.neuron.2009.06.026
3. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. *JAMA*. 1997;278(16):1349-1356. doi:10.1001/jama.1997.03550160069041

Test codes may vary by location. Please contact your local laboratory for more information.